• CSPC Pharmaceutical Group announced preliminary Phase I/II results for SYS6090 (JMT108), presented at the ESMO Congress on October 25, 2026.
• The experimental monotherapy showed preliminary antitumor activity in advanced solid tumors, including liver and colorectal cancers.
• Safety was manageable, with no unexpected safety signals during dose escalation.
• Phase II cohort enrollment remains ongoing to further evaluate the treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261027-12384620), on October 27, 2026, and is solely responsible for the information contained therein.